Does SECUKINUMAB Cause Injection site extravasation? 111 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 111 reports of Injection site extravasation have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.1% of all adverse event reports for SECUKINUMAB.
111
Reports of Injection site extravasation with SECUKINUMAB
0.1%
of all SECUKINUMAB reports
0
Deaths
3
Hospitalizations
How Dangerous Is Injection site extravasation From SECUKINUMAB?
Of the 111 reports, 3 (2.7%) required hospitalization.
Is Injection site extravasation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 111 reports have been filed with the FAERS database.
What Other Side Effects Does SECUKINUMAB Cause?
Drug ineffective (27,434)
Psoriasis (21,976)
Pain (15,244)
Arthralgia (13,769)
Fatigue (9,406)
Psoriatic arthropathy (8,900)
Pruritus (8,755)
Malaise (8,570)
Rash (8,023)
Condition aggravated (7,536)
What Other Drugs Cause Injection site extravasation?
EXENATIDE (2,320)
ETANERCEPT (1,139)
ADALIMUMAB (381)
SEMAGLUTIDE (342)
VEDOLIZUMAB (237)
SOMATROPIN (230)
REGADENOSON (226)
RITUXIMAB (215)
EVOLOCUMAB (188)
DUPILUMAB (170)
Which SECUKINUMAB Alternatives Have Lower Injection site extravasation Risk?
SECUKINUMAB vs SELADELPAR LYSINE
SECUKINUMAB vs SELEGILINE
SECUKINUMAB vs SELENIUM
SECUKINUMAB vs SELENIUM SULFIDE
SECUKINUMAB vs SELEXIPAG